Cargando…
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
PURPOSE: Cytoreductive therapy is beneficial in patients with essential thrombocythemia (ET) at high risk of thrombosis. However, its value in those lacking high-risk features remains unknown. This open-label, randomized trial compared hydroxycarbamide plus aspirin with aspirin alone in patients wit...
Autores principales: | Godfrey, Anna L., Campbell, Peter J., MacLean, Cathy, Buck, Georgina, Cook, Julia, Temple, Julie, Wilkins, Bridget S., Wheatley, Keith, Nangalia, Jyoti, Grinfeld, Jacob, McMullin, Mary Frances, Forsyth, Cecily, Kiladjian, Jean-Jacques, Green, Anthony R., Harrison, Claire N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269131/ https://www.ncbi.nlm.nih.gov/pubmed/30153096 http://dx.doi.org/10.1200/JCO.2018.78.8414 |
Ejemplares similares
-
Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?
por: Cattaneo, Marco
Publicado: (2023) -
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
por: Harrison, Claire N., et al.
Publicado: (2023) -
Coagulation status and determinants of possible aspirin resistance in patients with essential thrombocythemia
por: Yang, Erpeng, et al.
Publicado: (2022) -
Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease
por: Pedersen, Oliver Buchhave, et al.
Publicado: (2021) -
Thrombosis and Aspirin: Clinical Aspect, Aspirin in Cardiology, Aspirin in Neurology, and Pharmacology of Aspirin
por: Doutremepuich, Christian
Publicado: (2012)